Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
CT Senate Passes Sweeping Consumer Protection Bill The Connecticut Senate passed an expansive consumer protection bill ( SB 5 ). Among other things, the measure would require service providers such as...
Social Media Warning Label Legislation Catching on in States Although Congress hasn’t responded to former U.S. Surgeon General Vivek Murthy’s call last June to take up legislation requiring...
OR Lawmakers Pass Age Discrimination Bill Oregon’s legislature passed a bill ( HB 3187 ) that would prohibit an employer from requesting an applicant’s age, date of birth or date of graduation...
WI Assembly Passes Multiple Healthcare Bills Wisconsin’s Assembly passed multiple healthcare-related bills with broad bipartisan support. One ( AB 43 ) would allow pharmacists to prescribe birth...
A nightmare may be coming to life for social media companies in Minnesota. There, Democrats in the state Legislature have embraced a pioneering bill, SB 3197 , which seeks to levy the nation’s...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
Transitioning coverage of COVID-19 testing, treatment and vaccinations to commercial insurers poses significant challenges, according to experts gathered for a Kaiser Family Foundation webinar on the commercialization of COVID coverage last week.
For one thing, vaccines, tests and treatments won’t shift to the private sector on the same timeline, due to differences in their regulatory status.
“Medicare and Medicaid cover things differently if they’re approved versus whether they’re under emergency use authorization,” said Dawn O’Connell, assistant secretary for preparedness and response at the Department of Health and Human Services (HHS).
Incentivizing the private sector to keep on producing COVID vaccines, treatments and tests will be another major challenge.
“The government was essentially guaranteeing a market for tests, for treatments, for vaccines,” said Larry Levitt, KFF’s executive vice president for health policy. “We need to think about making sure that those countermeasures are available in a timely way and in adequate supply.”
Figuring out how to protect the uninsured is another issue facing policymakers, said Rena Conti, an assistant professor of markets, public policy and law at Boston University. She said those with insurance will still be able to get free COVID vaccinations after the government stops paying for them. And uninsured children will be covered under the Vaccines for Children Program. But “if you’re an uninsured adult, you’re kind of out of luck,” she said. (FIERCE HEALTHCARE)
The Department of Health and Human Services’ (HHS) Office for Civil Rights (OCR) is investigating complaints that some pharmacists at Walgreens and CVS have been refusing to fill prescriptions for certain medications. As a result of the Supreme Court’s recent abortion ruling and some state laws, the two pharmacy chains now permit their pharmacists to refuse to fill prescriptions based on moral grounds if they believe the prescribed medication will be used for an abortion. The medications the pharmacists are reportedly refusing to fill include those used for treating high blood sugar, rheumatoid arthritis, and severe acne. (FIERCE HEALTHCARE)
At least 18 percent of 92,000 opioid overdose deaths in 43 states and Washington, D.C., in 2019 and 2020 involved antihistamines, according to a study by the Centers for Disease Control and Prevention published in its Morbidity and Mortality Weekly Report. Over 71 percent of those antihistamine-related deaths involved diphenhydramine, better known by its brand name, Benadryl. (USA TODAY)
Wisconsin nursing education programs add roughly 3,000 nurses to the workforce each year. But the demand for nurses is far outpacing that rate. Based on preliminary data about 11 percent of RN positions and 17 percent of CNA positions in the state were unfilled last year, and the state is projecting a shortfall of nearly 20,000 nurses by 2035.
A lack of qualified faculty and limited classroom space are forcing programs to turn away applicants, a problem nationwide. Nursing schools turned away 80,407 qualified applicants in 2019, according to the American Association of Colleges of Nursing. (WISCONSIN PUBLIC RADIO)
A report released last week by Private Equity Stakeholder Project, a nonprofit group that analyzes the impact of private equity investments, indicated there were 27 private equity deals in the medical staffing space last year, more than double the 11 such investments in 2020. The report said those deals helped make it possible for travel nurse agencies to increase their rates. (FIERCE HEALTHCARE)
Planned Parenthood South Atlantic and other abortion rights groups have filed a petition asking a three-judge panel of the Wake County Superior Court to lift provisions of North Carolina state law preventing physician assistants, nurse practitioners and certified nurse-midwives from providing medication abortions. Since the Supreme Court overturned Roe v. Wade in June, abortion clinics in the state have experienced an influx of patients from neighboring states with more restrictive abortion laws. (RALEIGH NEWS & OBSERVER)
California Gov. Gavin Newsom (D) announced last week that on Feb. 28 he would be lifting the COVID-19 state of emergency declaration he imposed more than two-and-a-half years ago. State officials said that date would give healthcare providers more flexibility to deal with an anticipated winter surge in COVID-19 cases. (SACRAMENTO BEE)
The Food and Drug Administration’s advisory panel voted 14-1 last week that a drug intended to prevent premature births is ineffective and should be removed from the market. The FDA actually called for removal of the drug, Makena, in 2020, but its manufacturer, Covid Pharma, challenged that action pending further research.
A final decision is expected from FDA Commissioner Dr. Robert Califf in the coming months. If the drug is removed, it would be the first to meet that fate after receiving initial approval from the FDA on promising early data. (ASSOCIATED PRESS)
-- Compiled by KOREY CLARK